TerminatedPhase 1NCT04741542
Safety of SP-420 in the Treatment of Transfusional Iron Overload
Studying Rare hereditary hemochromatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Principal Investigator
- Supreet Kaur, MDThe University of Texas Health Science Center at San Antonio
- Intervention
- SP-420(drug)
- Enrollment
- 2 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2024
Study locations (1)
- Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States
Collaborators
Abfero Pharmaceuticals, Inc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04741542 on ClinicalTrials.govOther trials for Rare hereditary hemochromatosis
Additional recruiting or active studies for the same condition.